周田彦 - 北京大学

个人简介

分别于1992、1998、2006年在北京大学药学院获得学士、硕士及博士学位。曾到香港理工大学(2002.8-2004.9)和美国奥克拉荷马州立大学(2007.2-2008.8)作访问研究。1998年后在北京大学药学院药剂学系工作。长期从事定量药理学相关研究和应用，是北京大学/辉瑞公司定量药理学高级培训中心核心成员。现任京大学药学院教授、博士生导师，中国药理学会定量药理学专业委员会副主任委员，中国药理学会药物代谢专业委员会委员，北京药理学会药物代谢专业委员会副主任委员，国家食品与药品管理局评审专家，国家及省部级自然科学基金评审专家，药学学报编委，以及10余个国内外相关专业期刊的评审。主持近10项国家自然科学基金及北京市/教育部自然科学基金等纵向项目，以及20余项与药企/临床研究机构合作研究项目。发表论文120余篇，编写教材与专著6部，授权中国专利5项。主讲北大医学部课程《生物药剂学与药物动力学》与《高等药物动力学》，以及清华大学药学院课程《药动学/药效学》。

研究领域

基于机制的药物动力学/药效动力学/(PK/PD)；群体药物动力学/药效动力学；定量药理学在肿瘤疾病治疗及新药研发中的应用。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Li, J; Chen, R; Yao, QY; Liu, SJ; Tian, XY; Lu, W*; Zhou, TY*. Semi-mechanism-based pharmacokinetic-pharmacodynamic model for characterizing time-dependent pharmacokinetics of dexamethasone and its efficacy in the treatment of breast cancer. Acta Pharmacol Sin. 2018, online. 2. Chen, WJ; Chen, R; Li, J; Fu, Y; Yang, L; Su, H; Yao, Y; Li, L;Zhou, TY*; Lu, W*. Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models. J Pharmacol Exp Ther . 2018, 364(1), 13-25. 3. Hao, FR; Wang, SY; Zhu, X; Xue, JS; Li, JY; Wang, LJ; Li, J Lu, W; Zhou, TY*. Pharmacokinetic- pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft. Pharm Res. 2017, 34, 408-418. 4. Li, J; Yao, QY; Xue, JS; Wang, LJ; Yuan, Y; Tian, XY; Su, H; Wang, SY; Chen, WJ; Lu, W*;Zhou, TY*. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer. Acta Pharmacol Sin. 2017, 38(9), 1282-1296. 5. Yao, QY; Li, J; Yao,Y; Chen, R; Chen, WJ; Su, H, Yang, L; Xue, JS; Lu, W; Zhou, TY*. A highly sensitive LC-MS/MS method for the determination of 21-hydroxy deflazacort in nude mice plasma and its application to a pharmacokinetic study. J Chinese Pharm Sci . 2017, 26(6), 404-412. 6. Li, JY; Ren, YP; Yuan, Y; Ji SM; Zhou, SP; Wang, LJ; Mou Z; Li, L; Lu, W, Zhou, TY*. Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice. Acta Pharmacol Sin. 2016, 37(7), 930-940. 7. Wang, LJ; Li, J; Hao, FR; Yuan, Y; Li, JY; Lu, W;Zhou, TY*. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen. Acta Pharmacol Sin. 2016, 37(6), 845-856. 8. Ji, XW; Ji, SM; Li, RT; Wu, KH; Zhu, X; Lu, W*; Zhou, TY*. Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in breast cancer. Acta Pharmacol Sin, 2016, 37(6). 825-833. 9. Li, X; Chen Y; Zhao W; Lu, W*; Zhou, TY*. Pharmacokinetic/Pharmacodynamic Analysis of Metformin using Different in Diabetic Rats. Drug Res. 2016, 66(10), 547-554. 10. Mou, ZZ; Wang, SY; Su, QH; Yuan, Y; Li, JY; Wang, LJ; Yao, QY; Ji, SM; Lu, W*; Zhou, TY*. Cabozantinib enhances the response of NSCLC cells with wild-type EGFR to erlotinib and pharmacodynamic modeling of their sequential combinations. J Chinese Pharm Sci. 2016, 25(11), 799-813. 11. Hua, M; Ji, XW; Li, RT; Ji, SM; Li, J; Yao, QY; Wang, LJ; Hao, FR; Lu, W; Zhou, TY*. Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of TM208 on non-small cell lung cancer xenograft. J Chinese Pharm Sci. 2016, 25(7), 502-511. 12. Ma, YH; Li, J; Su, QH; Chen, WJ; Lu, W*; Zhou, TY*. A liquid chromatography-tandem mass spectrometric method for the determination of axitinib in nude mouse plasma: Development, validation and application to a pharmacokinetic study, J Chinese Pharm Sci. 2016, 25(5), 342-350. 13. Yuan, Y; Zhou, X; Ren, YP; Zhou, SP, Wang, LJ; Ji, SM; Hua, M; Li L; Lu, W; Zhou, TY*. Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer. J Pharm Sci . 2015, 104(12), 4399–4408. 14. Ji, XW; Chen, GP; Song, Y; Hua, M; Wang, LJ; Li, L; Yuan, Y; Wang, SY; Zhou, TY*; Lu, W. Intratumoral estrogen sulfotransferase induction contributes to the anti-breast cancer effects of the dithiocarbamate derivative TM208. Acta Pharmacol Sin. 2015, 36(10), 1246-55. 15. Wang, SY; Mou, ZZ; Ma, YH; Li, J; Li, JY; Ji, XW; Wu, KH; Li, L; Lu, W; Zhou, TY*. Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: involvement of eradicating cancer stem-like cells. Biochem Pharmacol. 2015, 95(2), 98-109. 16. Ji, XW; Zhou, TY; Lu, Y; Wei, MJ, Lu; W; Cho, William Cs. Breast cancer treatment and sulfotransferase. Expert Opinion on Therapeutic Targets. 2015, 19(6), 821-34. 17. Li, J; Yuan, Y; Fan, R; Su, QH; Wang, SY; Zhou, TY*; Lu, W. A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study. J AOAC INT . 2015, 98(4), 921-926. 18. Li, JY; Li, J; Wang, SY; Yuan, Y; Su, QH; Lu, W; Zhou, TY*. Simultaneous determination of sunitinib and its active metabolites N-desethylsunitinib (SU12662) in nude mice plasma by liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study. J Chinese Pharm Sci. 2015, 24(4), 217-224. 19. Yuan, Y; Zhou, X; Li, J; Ye, S., Ji, XW; Li, L; Zhou, TY*; and Lu, W. Development and validation of a highly sensitive LC-？MS？/MS method for the determination of dexamethasone in nude mice plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2015, 29(4), 578-83. 20. Shao, XY#; Li, J#; Wang, SY; Chen, GP; Xu, JJ; Ji, XW; Li, L; Lu, W; Zhou, TY*. Exogenous dopamine induces dehydroepiandrosterone sulfotranferase (rSULT2A1) in rat liver and changes the pharmacokinetic profile of moxifloxacin in rats. Drug Metab Pharmacok . 2015, 30, 97-104. 21. Li, XG; Zhao, ZG; Li, L; Zhou, TY*; and Lu, W*. Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats. Drug Deliv. 2015, 22(1), 86–93. 22. Shao, XY; Li, J; Wang, SY; Chen, GP; Xu, JJ; Ji, XW; Li, L; Lu, W; Zhou, TY*. Comparison of dopamine with levodopa in the induction of aryl sulfotransferases and estrogen sulfotransferase in rat liver. J Chinese Pharm Sci. 2014, 23(7), 471-479. 23. Xu, JJ; Wang, SY; Chen, Y; Chen, GP; Li ZQ; Shao, XY; Li, L; Lu, W; Zhou, TY*. Dopamine D1 receptor activation induces dehydroepiandrosterone sulfotransferase (SULT2A1) in HepG2 cells. Acta Pharmacol Sin . 2014, 35(7), 889-898. 24. Ji, XW; Li, RT; Li, ZQ; Li, L; Shao, XY; Wang, SY; Yuan, Y; Zhou, TY*; Lu, W*. Inhibition of autophosphorylation of EGFR plays an important role in the anti-breast cancer efficacy of a dithiocarbamate derivative TM208. Acta Pharmacol Sin. 2014, 35, 239–247. 25. Li, MY; Li, HQ; Cheng, XL; Wang, XP; Li, L; Zhou, TY*, and Lu, W*. Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction between Erlotinib and Gemcitabine. Pharm Res . 2013, 30, 1400-1408. 26. Zhou, TY; Huang, CQ; Chen, Y; Xu, JJ; Shanbhag, PD; Chen, GP. Methamphetamine Regulation of Sulfotransferase 1A1 and 2A1 Expression in Rat Brain Sections. Neurotoxicology . 2013, 34, 212-218. 27. Wu, Q; Li, MY; Li, HQ; Deng, CH; Li, L; Zhou, TY*, and Lu, W*. Pharmacokinetic and pharmacodynamic study of erlotinib based upon phosphorylated epidermal growth factor receptor and tumor volume in human non-small cell lung cancer xenograft mouse mode. Acta Pharmacol Sin. 2013, 34, 1427–1436. 28. Cheng, XL; Guo,LP; Li, ZQ; Li, L; Zhou, TY*, Lu, W*. A HPLC method for simultaneous determination of 5-aminoimidazole-4-carboxamide riboside and its active metabolite 5-aminoimidazole-4-carboxamide ribotide in tumor-bearing nude mice plasma and its application to pharmacokinetics study. J Chromatogr B. 2013, 915–916, 64–70. 29. Zhou, TY; Chen, Y; Huang, CQ; Chen, GP. Caffeine induction of sulfotransferases in rat liver and intestine. J Appl Toxicol . 2012, 32, 804-809. 30. Zhou, X; Shang, DW; Zhang, TL; Li, L;Zhou, TY*; Lu, W*. Modeling of Angiotensin II-Angiotensin-(1-7) Counterbalance in Disease Progression in Spontaneously Hypertensive Rats Treated With/Without Perindopril. Pharmacol Res . 2012, 66, 177-184. 31. Li, XG; Li, L; Wang, XP; Ren, YP; Zhou, TY*; Lu, W*. Application of Model-Based Methods to Characterize Exenatide-Loaded Double-Walled Microspheres: In Vivo Release, Pharmacokinetic/Pharmacodynamic Model, and In Vitro and In Vivo Correlation. J Pharm Sci . 2012, 101, 3946-3961. 32. Xu, JJ; Chen, Y; Li, L; Li, ZQ; Wang, CA;Zhou, TY*, Lu, W*. An improved HPLC method for the quantitation of 3′-phosphoadenosine 5′-phosphate (PAP) to assay sulfotransferase enzyme activity in HepG2 cells. J Pharmaceut Biomed Analysis . 2012, 62, 182-186. 33. Ji, XW; Chen, Y; Li, RT; Zhou, TY*; Lu, W*. A high-sensitivity LC-MS/MS method for determination of 4-methyl-piperazine-1-carbodithioc acid 3-cyano-3, 3-diphenylpropyl ester hydrochloride in rat plasma and its application to pharmacokinetics study. Biomed Chromatogr . 2012, 26, 1196-1201. 34. Li, XG; Li,L; Zhou,X; Chen,Y; Ren,YP; Zhou, TY*; Lu, W*. Pharmacokinetic/pharmacodynamic studies for exenatide in diabetic rats. Acta Pharmacol Sin. 2012, 33, 1379-1386. 35. Li, L; Li, ZQ; Deng, CH; Ning, MR; Li, HQ; Bi, SS; Zhou, TY* and Lu, W*. Mechanism-based Pharmacokinetic/Pharmacodynamic Model for CYP3A1/2 Induction by Dexamethasone in Rats. Acta Pharmacol Sin. 2012, 33, 127-136. 36. Li, MY; Wu, Q; Li, HQ; Ning, MR; Chen, Y; Li, L; Zhou, TY*; and Lu, W*. A high-sensitive LC-MS/MS method to determine the concentrations of erlotinib and its active metabolite OSI-420 in BALB/c nude mice simultaneously and its application to a pharmacokinetic study. J Chin Pharm Sci. 2012, 21, 296-303. 37. Chen, Y; Li, HQ; Xu, JJ; Jiu, XF; Deng, CH; Li, XG; Li, L; Xu, XQ; Zhou, TY*; and Lu, W*. Determination of metformin in diabetic rat plasma by an improved ion-pair high-performance liquid chromatography: Application to pharmacokinetic study, J Chin Pharm Sci. 2012, 21, 211-218. 38. Ning, MR; Li, L; Li, J; Li, ZQ; Li, RT; Zhou, TY*; Lu, W*. In-vitro screen of reversible and time-dependent inhibition of CYP3A by TM208 and TM209 in rat liver microsomes. Acta Pharm Sin B. 2012, 2, 179-185. 39. Shang, DW; Wang, XP; Zhao, XT; Huang, FM; Tian, GZ; Lu, W*; Zhou, TY*. Simultaneous determination of nitrendipine and hydrochlorothiazide in spontaneously hypertensive rat plasma using HPLC with on-line solid-phase extraction. J Chromatogr B . 2011, 879, 3459-3464． 40. Li, HQ; Li, MY; Li, ZQ; Li, L; Bi, SS; Deng, CH; Chen, R; Zhou, TY* and Lu, W*. New synthetic route of two active isomeric metabolites of erlotinib and their bioactivity studies against several tumor cell lines. Chin J Chem , 2011, 29, 1709-1714. 41. Jiu, XF; Shang, DW; Chen, Y; Li, XG; Wan, XM; Zhou, TY*; Lu, W*. A high performance liquid chromatography method for the quantitative determination assay of sitagliptin in rat plasma and its application in pharmacokinetics study. J Chin Pharm Sci. 2011, 20, 63-69. 42. Li, L; Li, ZQ; Li,HQ; Bi, SS; Li, Bo; Xu, JJ; Zhou, TY* and Lu, W*. Development of a quantitative real time PCR assay for absolute detection and quantification of CYP3A1 and CYP3A2 mRNA induction in rat liver. J Chin Pharm Sci. 2011, 20, 597-603. 43. Li, HQ; Chen, Y; Li, ZQ; Deng, CH; Li, L; Bi, SS; Li, MY; Zhou, TY*; Lu, W*. A high performance liquid chromatography method for the quantitative determination of erlotinib in the plasma of tumor bearing BALB/c nude mice and its application in a pharmacokinetic study. J Chin Pharm Sci. 2011, 20, 245-252. 44. Zhou, TY; Huang, CQ; Chen, Y; Shanbhag, PD; Chen, GP. Methamphetamine regulation of sulfotransferases in rat liver and brain. Am J Pharmacol Toxicol , 2010, 5, 125-132. 45. Zhou, TY; Li, XM; Ng, MTT; Wang, YF; Quek, NM; Luo, J; Yuan, WX; Tan, CH; Zeng, HQ; Li, TH. Synthesis and Characterization of Circular Structures of i-Motif Tagged with Fluoresceins. Bioconjugate Chem, 2009, 20, 644-647. 46. Zhou, TY; Wang, YF; Li, XM; Zhang, Q; Li, TH. Synthesis and characterization of a fluorescein-labeled circular G-quadruplex. B Chem Soc Jpn , 2006, 79(8), 1300-1302. 47. Zhou, TY; Chen, GS; Wang, YF; Zhang, Q; Yang, M; Li, TH. Synthesis of unimolecularly circular G-quadruplexes as prospective molecular probes. Nucleic Acids Res. 2004, 32, e173/1-e173/9.